Summary
0.80 0.02(3.18%)09/06/2024
Lucid Diagnostics Inc. Common Stock (LUCD)
Lucid Diagnostics Inc. Common Stock (LUCD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.18 | -0.69 | 2.14 | 11.72 | 9.16 | 22.26 | -82.13 | -99.96 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.80 | |
| Open | 0.78 | |
| High | 0.81 | |
| Low | 0.78 | |
| Volume | 69,008 | |
| Change | 0.02 | |
| Change % | 3.18 | |
| Avg Volume (20 Days) | 45,764 | |
| Volume/Avg Volume (20 Days) Ratio | 1.51 | |
| 52 Week Range | 1.04 - 1.85 | |
| Price vs 52 Week High | -56.62% | |
| Price vs 52 Week Low | -22.84% | |
| Range | 2.88 | |
| Gap Up/Down | -0.08 | |
Fundamentals | ||
| Market Capitalization (Mln) | 43 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 17.50 | |
| Book Value | 0.0000 | |
| Earnings Per Share | -1.3820 | |
| EPS Estimate Current Quarter | -0.3200 | |
| EPS Estimate Next Quarter | -0.1800 | |
| EPS Estimate Current Year | -1.3700 | |
| EPS Estimate Next Year | -0.8000 | |
| Diluted EPS (TTM) | -1.3820 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -94.5461 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 200,000 | |
| Revenue per share TTM | 0.0140 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 1,218.2595 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 36,808,600 | |
| Shares Float | 7,160,018 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 80.55 | |
| Institutions (%) | 3.88 | |
09/03 07:51 EST - prnewswire.com
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the execution of a memorandum of understanding (MOU) with Front Line Mobile Health ("Front Line"), a comprehensive medical care provider for first responders.
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the execution of a memorandum of understanding (MOU) with Front Line Mobile Health ("Front Line"), a comprehensive medical care provider for first responders.
08/20 08:16 EST - prnewswire.com
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of an analytical validation study of its EsoGuard® Esophageal DNA test for the diagnosis of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) on samples collected non-endoscopically using Lucid's EsoCheck® Esophageal Cell Collection Device. The manuscript, entitled Analytical Validation of a DNA Methylation Biomarker Test for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma from Samples Collected Using EsoCheck®, a Non-Endoscopic Esophageal Cell Collection Device , has been published in the peer-reviewed journal Diagnostics , and is currently available via open access online.
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of an analytical validation study of its EsoGuard® Esophageal DNA test for the diagnosis of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) on samples collected non-endoscopically using Lucid's EsoCheck® Esophageal Cell Collection Device. The manuscript, entitled Analytical Validation of a DNA Methylation Biomarker Test for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma from Samples Collected Using EsoCheck®, a Non-Endoscopic Esophageal Cell Collection Device , has been published in the peer-reviewed journal Diagnostics , and is currently available via open access online.
08/13 08:16 EST - prnewswire.com
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK , Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the American Foregut Society (AFS), a leading society of gastroenterologists and surgeons collaborating to improve patient outcomes, including in esophageal disease, has formally requested that health insurance providers update their medical policies to include the EsoGuard® Esophageal DNA test as a covered service. The open letter, posted on the society website, highlights the critical need for early detection of esophageal precancer (Barrett's Esophagus or BE) to prevent highly lethal esophageal cancer, the strong scientific evidence supporting the use of EsoGuard as a minimally invasive screening alternative to endoscopy, and EsoGuard's incorporation in the practices of AFS physicians.
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer NEW YORK , Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the American Foregut Society (AFS), a leading society of gastroenterologists and surgeons collaborating to improve patient outcomes, including in esophageal disease, has formally requested that health insurance providers update their medical policies to include the EsoGuard® Esophageal DNA test as a covered service. The open letter, posted on the society website, highlights the critical need for early detection of esophageal precancer (Barrett's Esophagus or BE) to prevent highly lethal esophageal cancer, the strong scientific evidence supporting the use of EsoGuard as a minimally invasive screening alternative to endoscopy, and EsoGuard's incorporation in the practices of AFS physicians.
08/13 08:01 EST - prnewswire.com
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program Veris Health actively pursuing financing following launch of pilot program with The Ohio State's James Cancer Hospital Conference call and webcast to be held today, August 13 th at 8:30 AM EDT NEW YORK , Aug. 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended June 30, 2024. Conference Call and Webcast The webcast will take place on Tuesday, August 13, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program Veris Health actively pursuing financing following launch of pilot program with The Ohio State's James Cancer Hospital Conference call and webcast to be held today, August 13 th at 8:30 AM EDT NEW YORK , Aug. 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended June 30, 2024. Conference Call and Webcast The webcast will take place on Tuesday, August 13, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
08/12 13:32 EST - seekingalpha.com
Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Dr. Lishan Aklog - Chairman, Chief Executive Officer Dennis McGrath - Chief Financial Officer Matt Riley - Director of Investor Relations Conference Call Participants Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Anthony Vendetti - Maxim Group Mark Massaro - BTIG Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Second Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Dr. Lishan Aklog - Chairman, Chief Executive Officer Dennis McGrath - Chief Financial Officer Matt Riley - Director of Investor Relations Conference Call Participants Kyle Mikson - Canaccord Ross Osborn - Cantor Fitzgerald Anthony Vendetti - Maxim Group Mark Massaro - BTIG Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Second Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
08/12 08:07 EST - prnewswire.com
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
EsoGuard® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement Over 50 high-volume #CheckYourFoodTube Precancer Testing Events in 2Q24, including first with upfront contracted payment Conference call and webcast to be held today, August 12 th at 8:30 AM EDT NEW YORK , Aug. 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended June 30, 2024. Conference Call and Webcast The webcast will take place on Monday, August 12, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
EsoGuard® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement Over 50 high-volume #CheckYourFoodTube Precancer Testing Events in 2Q24, including first with upfront contracted payment Conference call and webcast to be held today, August 12 th at 8:30 AM EDT NEW YORK , Aug. 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended June 30, 2024. Conference Call and Webcast The webcast will take place on Monday, August 12, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
08/08 08:31 EST - prnewswire.com
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
Event held at Fort Worth Fire Department in partnership with Front Line Mobile Health NEW YORK , Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the successful completion of a #CheckYourFoodTube Precancer Testing Event in partnership with the Fort Worth Fire Department (FWFD) and Front Line Mobile Health ("Front Line"), a comprehensive medical care provider for first responders. This was Lucid's first major directly-contracted #CheckYourFoodTube event.
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
Event held at Fort Worth Fire Department in partnership with Front Line Mobile Health NEW YORK , Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the successful completion of a #CheckYourFoodTube Precancer Testing Event in partnership with the Fort Worth Fire Department (FWFD) and Front Line Mobile Health ("Front Line"), a comprehensive medical care provider for first responders. This was Lucid's first major directly-contracted #CheckYourFoodTube event.
08/06 08:15 EST - prnewswire.com
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the release of new real-world data from its ENVET-BE study supporting the clinical utility of the EsoGuard® Esophageal DNA test as a non-invasive triage tool to significantly increase the positive yield of invasive upper endoscopy (EGD) for detection of esophageal precancer (Barrett's Esophagus or BE) and cancer. The manuscript entitled Enhancing the Positive Predictive Value of EGD for Diagnosis of Barrett's Esophagus Through EsoGuard® Triage , is currently available on the leading health sciences preprint server, MedRxiv, while undergoing peer review for publication.
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the release of new real-world data from its ENVET-BE study supporting the clinical utility of the EsoGuard® Esophageal DNA test as a non-invasive triage tool to significantly increase the positive yield of invasive upper endoscopy (EGD) for detection of esophageal precancer (Barrett's Esophagus or BE) and cancer. The manuscript entitled Enhancing the Positive Predictive Value of EGD for Diagnosis of Barrett's Esophagus Through EsoGuard® Triage , is currently available on the leading health sciences preprint server, MedRxiv, while undergoing peer review for publication.
08/05 08:15 EST - prnewswire.com
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK , Aug. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Dates: August 12-13, 2024 Canaccord Genuity 44th Annual Growth Conference Fireside Chat: Tuesday, August 13, 2024, at 1:30 PM ET The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK , Aug. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Dates: August 12-13, 2024 Canaccord Genuity 44th Annual Growth Conference Fireside Chat: Tuesday, August 13, 2024, at 1:30 PM ET The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.
07/29 08:15 EST - prnewswire.com
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, August 12, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, August 12, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
07/29 06:00 EST - investorplace.com
3 Hypergrowth Stocks That Speculators Should Keep Tabs On
Hypergrowth stocks isn't so much about returns as it is time. Don't get me wrong: when you think about the words “hyper” and “growth,” the price moving in the northward direction along the y-axis is crucial.
3 Hypergrowth Stocks That Speculators Should Keep Tabs On
Hypergrowth stocks isn't so much about returns as it is time. Don't get me wrong: when you think about the words “hyper” and “growth,” the price moving in the northward direction along the y-axis is crucial.
07/23 08:01 EST - prnewswire.com
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Quarterly EsoGuard® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it performed a record number of commercial EsoGuard® Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter.
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Quarterly EsoGuard® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it performed a record number of commercial EsoGuard® Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter.
07/11 08:31 EST - prnewswire.com
Lucid Diagnostics Launches New Corporate Website
NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the launch of its newly redesigned corporate website, www.luciddx.com. "We designed the new website to highlight our mission to prevent esophageal cancer and offer patients, healthcare professionals, investors, and other interested parties a user-friendly experience with easily accessible, informative content on Lucid and its innovative technologies," said Jenna Mowatt, Vice President of Marketing and Communications at Lucid Diagnostics.
Lucid Diagnostics Launches New Corporate Website
NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the launch of its newly redesigned corporate website, www.luciddx.com. "We designed the new website to highlight our mission to prevent esophageal cancer and offer patients, healthcare professionals, investors, and other interested parties a user-friendly experience with easily accessible, informative content on Lucid and its innovative technologies," said Jenna Mowatt, Vice President of Marketing and Communications at Lucid Diagnostics.
07/04 12:31 EST - zacks.com
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
07/02 07:55 EST - prnewswire.com
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Prospective screening study demonstrates excellent EsoGuard sensitivity of 87.5% and negative predictive value (NPV) of 98.6% Previously announced positive data from a separate prospective VA screening study also accepted for peer-reviewed publication Studies further strengthen EsoGuard's clinical validity data in support of upcoming Medicare LCD pre-submission meeting and ongoing commercial payor engagements NEW YORK , July 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from its ESOGUARD BE-1 prospective, international, multicenter, single-arm study conducted to clinically validate performance of the EsoGuard® Esophageal DNA test on samples collected with the EsoCheck® Esophageal Cell Collection Device for detection of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) in a screening population. This is the second clinical validation study in a screening population following previously announced positive data from the Cleveland VA screening study, which was recently accepted for peer-reviewed publication.
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Prospective screening study demonstrates excellent EsoGuard sensitivity of 87.5% and negative predictive value (NPV) of 98.6% Previously announced positive data from a separate prospective VA screening study also accepted for peer-reviewed publication Studies further strengthen EsoGuard's clinical validity data in support of upcoming Medicare LCD pre-submission meeting and ongoing commercial payor engagements NEW YORK , July 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from its ESOGUARD BE-1 prospective, international, multicenter, single-arm study conducted to clinically validate performance of the EsoGuard® Esophageal DNA test on samples collected with the EsoCheck® Esophageal Cell Collection Device for detection of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) in a screening population. This is the second clinical validation study in a screening population following previously announced positive data from the Cleveland VA screening study, which was recently accepted for peer-reviewed publication.
06/12 08:05 EST - prnewswire.com
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part of a #CheckYourFoodTube Precancer Testing Event. In partnership with physicians from Mass General Brigham, Boston's Local 718 International Association of Fire Fighters (IAFF) hosted its first #CheckYourFoodTube event to ensure its at-risk firefighters could be tested for esophageal precancer.
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part of a #CheckYourFoodTube Precancer Testing Event. In partnership with physicians from Mass General Brigham, Boston's Local 718 International Association of Fire Fighters (IAFF) hosted its first #CheckYourFoodTube event to ensure its at-risk firefighters could be tested for esophageal precancer.
05/20 06:00 EST - investorplace.com
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
No matter what anyone says, the very concept of penny stocks to buy must be treated with extreme skepticism. I'm not talking about having an aggressive mistrust toward such enterprises.
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
No matter what anyone says, the very concept of penny stocks to buy must be treated with extreme skepticism. I'm not talking about having an aggressive mistrust toward such enterprises.
05/13 20:43 EST - prnewswire.com
PAVmed Provides Business Update and First Quarter 2024 Financial Results
Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Conference call and webcast to be held tomorrow, May 14 th at 8:30 AM EDT NEW YORK , May 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2024. Conference Call and Webcast The webcast will take place on Tuesday, May 14, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
PAVmed Provides Business Update and First Quarter 2024 Financial Results
Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Conference call and webcast to be held tomorrow, May 14 th at 8:30 AM EDT NEW YORK , May 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2024. Conference Call and Webcast The webcast will take place on Tuesday, May 14, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
05/13 13:01 EST - seekingalpha.com
Lucid Diagnostics Inc. (LUCD) Q1 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Mike Matson - Needham Anthony Vendetti - Maxim Group Vidyun Bais - BTIG Kyle Mikson - Canaccord Edward Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics First Quarter 2024 Business Update Conference Call. At this time all lines are in listen only mode.
Lucid Diagnostics Inc. (LUCD) Q1 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Mike Matson - Needham Anthony Vendetti - Maxim Group Vidyun Bais - BTIG Kyle Mikson - Canaccord Edward Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics First Quarter 2024 Business Update Conference Call. At this time all lines are in listen only mode.
05/07 07:39 EST - prnewswire.com
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK , May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million.
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK , May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million.